Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
6.0
Journals
Cells
Special Issues
The Role of Androgen Receptor in Prostate Cancer—Revisited
share announcement

The Role of Androgen Receptor in Prostate Cancer—Revisited

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Nuclei: Function, Transport and Receptors".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 3078

Special Issue Editor

Prof. Hiroshi Miyamoto

E-Mail Website
Guest Editor
Director of Genitourinary Pathology, University of Rochester Medical Center, Rochester, NY, USA
Interests: nuclear hormone receptors; androgen receptor; glucocorticoid receptor; antiandrogens; glucocorticoids; urothelial cancer; prostate cancer; genitourinary pathology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Androgens are known to have widespread physiological actions beyond the reproductive system via binding to the androgen receptor which is a member of the nuclear receptor superfamily that functions as a ligand-inducible transcription factor. Meanwhile, the role of the androgen receptor has been widely studied in prostate cancer. Additionally, since its discovery over 80 years ago, androgen deprivation therapy remains the mainstay of medical treatment for advanced prostate cancer. Nonetheless, the exact functions of the androgen receptor in the development and progression of prostate cancer, as well as the castration resistant state primarily following androgen deprivation therapy, are not fully characterized. The aim of this Special Issue is to provide an overview of current preclinical and clinical findings indicating the involvement of androgen receptor signals in prostate cancer. Original research or review articles on signaling related to androgens and/or the androgen receptor in prostate cancer would be most welcome.

Hiroshi Miyamoto, MD, PhD
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • androgens
  • androgen receptor
  • prostate cancer
  • androgen deprivation therapy
  • castration resistance

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

22 pages, 2372 KiB  
Review
Regulating Androgen Receptor Function in Prostate Cancer: Exploring the Diversity of Post-Translational Modifications
by Lance Edward V. Lumahan, Mazia Arif, Amy E. Whitener and Ping Yi
Cells 2024, 13(2), 191; https://doi.org/10.3390/cells13020191 - 19 Jan 2024
Viewed by 1013
Abstract
Androgen receptor (AR) transcriptional activity significantly influences prostate cancer (PCa) progression. In addition to ligand stimulation, AR transcriptional activity is also influenced by a variety of post-translational modifications (PTMs). A number of oncogenes and tumor suppressors have been observed leveraging PTMs to influence [...] Read more.
Androgen receptor (AR) transcriptional activity significantly influences prostate cancer (PCa) progression. In addition to ligand stimulation, AR transcriptional activity is also influenced by a variety of post-translational modifications (PTMs). A number of oncogenes and tumor suppressors have been observed leveraging PTMs to influence AR activity. Subjectively targeting these post-translational modifiers based on their impact on PCa cell proliferation is a rapidly developing area of research. This review elucidates the modifiers, contextualizes the effects of these PTMs on AR activity, and connects these cellular interactions to the progression of PCa. Full article
(This article belongs to the Special Issue The Role of Androgen Receptor in Prostate Cancer—Revisited)
►▼ Show Figures

Figure 1

17 pages, 1822 KiB  
Review
Therapeutic Approaches to Targeting Androgen Receptor Splice Variants
by Violet A. Daniels, Jun Luo, Channing J. Paller and Mayuko Kanayama
Cells 2024, 13(1), 104; https://doi.org/10.3390/cells13010104 - 04 Jan 2024
Viewed by 1487
Abstract
Therapeutic options for advanced prostate cancer have vastly expanded over the last decade and will continue to expand in the future. Drugs targeting the androgen receptor (AR) signaling pathway, i.e., androgen receptor targeting agents (ARTAs), remain the mainstream treatments that are increasingly transforming [...] Read more.
Therapeutic options for advanced prostate cancer have vastly expanded over the last decade and will continue to expand in the future. Drugs targeting the androgen receptor (AR) signaling pathway, i.e., androgen receptor targeting agents (ARTAs), remain the mainstream treatments that are increasingly transforming the disease into one that can be controlled for an extended period of time. Prostate cancer is inherently addicted to AR. Under the treatment pressure of ARTA, molecular alterations occur, leading to the clonal expansion of resistant cells in a disease state broadly categorized as castration-resistant prostate cancer (CRPC). One castration resistance mechanism involves AR splice variants (AR-Vs) lacking the ligand-binding domain. Some AR-Vs have been identified as constitutively active, capable of activating AR signaling pathways without androgenic ligands. Among these variants, AR-V7 is the most extensively studied and may be measured non-invasively using validated circulating tumor cell (CTC) tests. In the context of the evolving prostate cancer treatment landscape, novel agents are developed and evaluated for their efficacy in targeting AR-V7. In patients with metastatic CRPC (mCRPC), the availability of the AR-V7 tests will make it possible to determine whether the treatments are effective for CTC AR-V7-positive disease, even though the treatments may not be specifically designed to target AR-V7. In this review, we will first outline the current prostate cancer treatment landscape, followed by an in-depth review of relatively newer prostate cancer therapeutics, focusing on AR-targeting agents under clinical development. These drugs are categorized from the standpoint of their activities against AR-V7 through direct or indirect mechanisms. Full article
(This article belongs to the Special Issue The Role of Androgen Receptor in Prostate Cancer—Revisited)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop